Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own0.50% Shs Outstand145.93M Perf Week2.61%
Market Cap8.84B Forward P/E- EPS next Y-1.08 Insider Trans57.03% Shs Float145.58M Perf Month-3.13%
Income-174.70M PEG- EPS next Q-0.41 Inst Own- Short Float3.62% Perf Quarter6.15%
Sales572.10M P/S15.46 EPS this Y-34.70% Inst Trans-0.29% Short Ratio4.09 Perf Half Y-14.47%
Book/sh10.14 P/B5.98 EPS next Y37.20% ROA-8.90% Target Price82.38 Perf Year-5.05%
Cash/sh6.08 P/C9.96 EPS next 5Y25.00% ROE-13.10% 52W Range55.04 - 84.25 Perf YTD-13.86%
Dividend- P/FCF- EPS past 5Y-44.30% ROI-8.50% 52W High-28.07% Beta0.94
Dividend %- Quick Ratio6.90 Sales past 5Y13.10% Gross Margin82.90% 52W Low10.10% ATR1.99
Employees1341 Current Ratio8.00 Sales Q/Q18.50% Oper. Margin-25.10% RSI (14)51.96 Volatility2.92% 3.18%
OptionableYes Debt/Eq0.45 EPS Q/Q16.10% Profit Margin-30.50% Rel Volume0.74 Prev Close61.46
ShortableYes LT Debt/Eq0.45 EarningsJul 30 AMC Payout- Avg Volume1.29M Price60.60
Recom2.00 SMA200.03% SMA500.50% SMA200-8.87% Volume955,200 Change-1.40%
19-Feb-14Reiterated Barclays Equal Weight $73 → $76
14-Jan-14Reiterated Deutsche Bank Buy $75 → $85
10-Jan-14Downgrade Barclays Overweight → Equal Weight $75 → $73
25-Oct-13Reiterated Barclays Overweight $70 → $75
18-Sep-13Downgrade Stifel Buy → Hold
26-Jul-13Reiterated Stifel Buy $67 → $70
03-Apr-13Reiterated Barclays Overweight $54 → $70
20-Mar-13Reiterated RBC Capital Mkts Outperform $58 → $64
20-Mar-13Reiterated Deutsche Bank Hold $45 → $59
22-Feb-13Reiterated RBC Capital Mkts Outperform $55 → $58
01-Feb-13Reiterated UBS Buy $53 → $67
22-Jan-13Upgrade Stifel Nicolaus Hold → Buy $67
06-Nov-12Reiterated Barclays Overweight $46 → $54
06-Nov-12Downgrade Brean Capital Buy → Hold
28-Sep-12Reiterated Summer Street Research Buy $45 → $52
27-Aug-12Downgrade Deutsche Bank Buy → Hold $40 → $45
24-Aug-12Initiated Barclays Overweight $46
12-Apr-12Initiated UBS Buy $43
26-Mar-12Initiated Canaccord Genuity Buy $43
19-Mar-12Upgrade Brean Murray Hold → Buy $41
23-Jul-14 02:15PM  [video] What's coming in biotech? at CNBC
12:20PM  Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines Zacks
12:10PM  Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales Zacks
08:00AM  Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation GlobeNewswire
18-Jul-14 08:21AM  Zacks Rank #1 Additions for Friday Zacks +5.88%
16-Jul-14 03:30PM  Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent Zacks
15-Jul-14 06:04AM  Cramer's Lightning Round - BioMarin Deserves To Be Higher (7/14/14) at Seeking Alpha
06:00AM  'Mad Money' Lightning Round: Wait on Whole Foods at TheStreet
14-Jul-14 06:52PM  Lightning Round: Whole Foods, Apache & more at CNBC
03:45PM  Will Johnson & Johnson (JNJ) Beat this Earnings Season? Zacks
09-Jul-14 08:00AM  BioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday, July 30 at 4:30pm ET GlobeNewswire
08-Jul-14 05:10PM  BioMarin's Vimizim Gets Canadian Nod Zacks
07-Jul-14 08:00AM  BioMarin Announces Health Canada Approval of VIMIZIM (elosulfase alfa) for the Treatment of Morquio A Syndrome PR Newswire
08:00AM  BioMarin Announces Health Canada Approval of VIMIZIM (elosulfase alfa) for the Treatment of Morquio A Syndrome CNW Group
03-Jul-14 07:06AM  Why BioMarin Pharmaceutical (BMRN) Could Beat Earnings Estimates Again Zacks
30-Jun-14 05:00PM  Biogen Hemophilia Drugs Launch Into The Unknown at Investor's Business Daily
02:06AM  Lifting the Curtain on Healthcare's Most Expensive Drugs at Motley Fool
20-Jun-14 02:19PM  Biomarin Pharmaceutical (BMRN) Marked As A Barbarian At The Gate at TheStreet +5.90%
02:19PM  Biomarin Pharmaceutical (BMRN) Marked As A Barbarian At The Gate
12-Jun-14 02:11PM  Amicus Therapeutics Still A "Show Me" Story at Seeking Alpha
02:11PM  Amicus Therapeutics Still A "Show Me" Story
08:30AM  Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More at 24/7 Wall St.
07:53AM  How Will BioMarin (BMRN) Stock Respond To This Analyst Upgrade Today? at TheStreet
07:53AM  How Will BioMarin (BMRN) Stock Respond To This Analyst Upgrade Today?
10-Jun-14 11:02AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a EDGAR Online
11:02AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
08:00AM  BioMarin to Present at the Wells Fargo Healthcare Conference on June 17th GlobeNewswire
08:00AM  BioMarin to Present at the Wells Fargo Healthcare Conference on June 17th
09-Jun-14 07:54AM  How WIll This Upgrade Affect Biomarin Pharmaceutical (BMRN) Stock Today? at TheStreet
07:54AM  How WIll This Upgrade Affect Biomarin Pharmaceutical (BMRN) Stock Today?
03-Jun-14 01:02PM  Drugs Stocks On The Rise With Help From 3 Stocks at TheStreet +6.17%
01:02PM  Drugs Stocks On The Rise With Help From 3 Stocks
12:01PM  Life After Pfizer: AstraZeneca Hopes for Oncology Success at Motley Fool
12:01PM  Life After Pfizer: AstraZeneca Hopes for Oncology Success
29-May-14 10:40AM  BioMarin's Pipeline Advances Zacks
10:40AM  BioMarin's Pipeline Advances
28-May-14 08:32AM  Retrophin Names Aselage COO at theflyonthewall.com
08:32AM  Retrophin Names Aselage COO
27-May-14 08:40AM  BioMarin doses first patient in Phase 3 INSPIRE trial with BMN 701 at theflyonthewall.com
08:00AM  BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease GlobeNewswire
23-May-14 08:31AM  BioMarin has a conference call hosted by JPMorgan at theflyonthewall.com
15-May-14 09:47AM  Temasek Boosted Stake in U.S. Health Care Industry Last Quarter at Bloomberg
06:47AM  BioMarin data compares well as monotherapy, says William Blair at theflyonthewall.com
05:40AM  ASCO abstracts 'surprisingly bland,' says Piper Jaffray at theflyonthewall.com
14-May-14 10:30AM  Insider Trading Alert - WMGI, MSM And BMRN Traded By Insiders at TheStreet
09-May-14 01:04PM  BIOMARIN PHARMACEUTICAL INC Financials EDGAR Online Financials
08-May-14 06:00AM  'Mad Money' Lightning Round: BioMarin Is for Real at TheStreet
04:29AM  Cramer's Lightning Round - BioMarin Is A Biotech Survivor (5/7/14) at Seeking Alpha
06-May-14 06:48PM  Lightning Round: Westport Innovations, Opko & More at CNBC
08:00AM  BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th GlobeNewswire
02-May-14 03:00PM  Loss at BioMarin Narrower Than Expected Zacks
12:16PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
09:13AM  BioMarin says change ups chance to hit cognition endpoint, says Janney Capital at theflyonthewall.com
06:11AM  BioMarin says BMN 165-302 study to be available in Q4 of 2015 theflyonthewall.com
12:50AM  BioMarin Pharmaceutical's CEO Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
01-May-14 06:14PM  BioMarin's Q1 Loss Shrinks 79% Due to Higher Rare Disease Drug Sales at Motley Fool
04:49PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:05PM  BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress GlobeNewswire
09:32AM  Today's Biotech Stocks to Watch: BioMarin Pharmaceutical Inc, InterMune, Inc. and Seattle Genetics Inc. at Motley Fool
07:07AM  Q1 2014 BioMarin Pharmaceutical Inc. Earnings Release - After Market Close CCBN
29-Apr-14 06:32PM  Better Biotech Buy: Vertex Pharmaceuticals Incorporated vs. BioMarin Pharmaceutical Inc. at Motley Fool
28-Apr-14 06:36PM  Cramer: Momentum stocks to fall much further? at CNBC
03:18PM  Cancer and Hepatitis C Treatment Breakthroughs Boost Pharma Stocks: Citigroup Investment Global Head of Healthcare Research & Analysis Andrew Baum, M.D. Interviews with the Wall Street Transcript Wall Street Transcript
01:08PM  Obamacare Worries Subside as Orphan Drugs and Oncology Treatments Retain Pricing Power: A Wall Street Transcript Interview with Boris Peaker, Ph.D., Executive Director and Senior Analyst with Oppenheimer & Co. Covering the Biotechnology Sec Wall Street Transcript
11:06AM  BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages GlobeNewswire
23-Apr-14 08:48AM  Do The Math: Ram Selvaraju On The Appeal Of Biotechs In Orphan Diseases at Seeking Alpha
17-Apr-14 06:32PM  How Are Orphan Drugmakers Faring in the Great Biotech Downturn? at Motley Fool
16-Apr-14 09:07AM  Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data Zacks +5.43%
08:00AM  BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET GlobeNewswire
14-Apr-14 06:15PM  [video] The IPO plague at CNBC
08:22AM  BioMarin says FDA extends Kuvan market exclusivity by six months theflyonthewall.com
08:00AM  FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets GlobeNewswire
11-Apr-14 06:25AM  Cramer's Lightning Round - The IPOs Are A Curse On The Market (4/10/14) at Seeking Alpha -6.59%
06:00AM  'Mad Money' Lightning Round: I Don't See a BioMarin Rally at TheStreet
10-Apr-14 06:44PM  Lightning Round: BioMarin, Carriage Services & More at CNBC -6.85%
03:03PM  'Very Volatile' Biotech, in Chart Form at The Wall Street Journal
07-Apr-14 09:03AM  The AACR Annual Meeting May Move These 2 Stocks at Motley Fool
04-Apr-14 08:31AM  Venture Capitalist Ran Nussbaum Brings Big Finance To Little Biotechs at Seeking Alpha
02-Apr-14 11:55AM  Uniqure rises after Baxter acquires Chatham Therapeutics at theflyonthewall.com
28-Mar-14 01:03PM  3 Stocks Pushing The Health Care Sector Downward at TheStreet
27-Mar-14 11:02AM  Biomarin Pharmaceutical (BMRN) Showing Signs Of Being A Roof Leaker at TheStreet
26-Mar-14 06:00AM  Once Seen As Too Scary, Editing People's Genes With Viruses Makes A $618 Million Comeback at Forbes
06:00AM  Gene Therapy's Big Comeback at Forbes
25-Mar-14 12:46PM  Biotech comeback stalls as Wall Street starts to worry at MarketWatch
12:19PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
11:01AM  Jim Cramer: Wait for the All-Clear at TheStreet
07:20AM  Wait for the All-Clear TheStreet
06:53AM  BioMarin pullback a buying opportunity, says RW Baird theflyonthewall.com
21-Mar-14 08:00AM  BioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors GlobeNewswire -5.91%
20-Mar-14 08:20AM  Narrower-than-Expected Loss at Catalyst Pharma Zacks
19-Mar-14 06:32PM  Shorts Piling on to Myriad Genetics: Time to Panic? at Motley Fool
13-Mar-14 05:12PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisi EDGAR Online
11-Mar-14 09:12PM  Company Makes Drug Available To Ailing Boy Following Public Outcry at Forbes
06-Mar-14 05:13PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S EDGAR Online
05-Mar-14 08:00AM  BioMarin Announces Pricing of Public Offering of Common Stock GlobeNewswire
04-Mar-14 04:23PM  BioMarin files to sell 1.5M shares of common stock at theflyonthewall.com
04:23PM  BioMarin files to sell 1.5M shares of common stock
04:21PM  BioMarin Announces Public Offering of Common Stock GlobeNewswire
01:04PM  BIOMARIN PHARMACEUTICAL INC Financials EDGAR Online Financials
08:00AM  BioMarin to Present at the Barclays Global Healthcare Conference in Miami GlobeNewswire
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerJun 04Sale62.521,00062,521178,257Jun 05 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 03Sale59.881,00059,876179,257Jun 05 07:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 02Sale57.8337721,80420,190Jun 03 06:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 22Sale56.881,00056,87646,195May 23 12:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 21Sale56.191,54586,81747,195May 22 06:27 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 16Sale56.861,864105,99460,950May 19 06:28 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 16Sale56.911,00457,13620,980May 19 06:27 PM
LAWLIS V BRYANDirectorMay 16Sale56.871,70096,6729,700May 19 06:31 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale58.231,43483,49864,850May 14 07:58 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 13Sale58.1847827,80923,080May 14 07:20 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 09Sale57.9662135,99224,080May 13 04:44 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 09Sale57.913,479201,47467,850May 12 04:46 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 01Sale59.5566639,66125,380May 05 04:00 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 01Sale59.6771542,66673,850May 05 08:06 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 28Option Exercise12.992,00025,98048,740Apr 01 07:41 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Option Exercise27.2417,370473,16542,750Mar 10 06:16 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Sale78.6317,3701,365,83125,380Mar 10 06:16 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Option Exercise39.068,000312,48072,273Mar 05 04:40 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Sale80.328,000642,53064,273Mar 05 04:40 PM
Davis George EricSVP, General CounselFeb 20Option Exercise21.5120,000430,20080,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 20Sale80.008,000640,00046,740Feb 24 06:54 PM
Davis George EricSVP, General CounselFeb 20Sale80.0020,0001,600,00060,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 06Option Exercise12.994,00051,96054,740Feb 07 04:53 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Option Exercise21.5110,000215,10052,350Feb 04 06:25 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Sale67.7010,000676,96642,350Feb 04 06:25 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise12.995,00064,95055,740Jan 14 07:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale70.005,000350,00050,740Jan 14 07:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Option Exercise12.9910,000129,90060,740Jan 08 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Sale67.4110,000674,09650,740Jan 08 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 02Option Exercise12.995,00064,95055,740Jan 06 04:08 PM
FUCHS HENRY JEVP, Chief Medical OfficerJan 02Sale68.9791663,17242,350Jan 06 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 02Sale68.905,000344,48350,740Jan 06 04:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale68.7110,000687,14350,740Dec 27 12:07 PM
GREY MICHAEL GDirectorDec 11Option Exercise21.7130,000651,30053,050Dec 13 06:07 PM
GREY MICHAEL GDirectorDec 11Sale69.6630,0002,089,68023,050Dec 13 06:07 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 09Option Exercise19.4413,026253,18327,906Dec 11 07:15 PM
LEWIS ALANDirectorDec 09Option Exercise30.5222,500686,77541,800Dec 11 08:21 PM
LAWLIS V BRYANDirectorDec 09Sale69.762,900202,30111,400Dec 11 07:17 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 09Sale69.5513,026906,01014,880Dec 11 07:15 PM
LEWIS ALANDirectorDec 09Sale69.9122,5001,572,98219,300Dec 11 08:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 05Sale69.705,000348,48550,740Dec 09 07:42 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerDec 02Option Exercise39.069,000351,54046,950Dec 04 04:15 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerDec 02Sale70.149,000631,27337,950Dec 04 04:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 14Option Exercise12.995,00064,95050,740Nov 18 05:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 05Option Exercise12.995,00064,95050,740Nov 07 05:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 05Sale62.365,000311,77945,740Nov 07 05:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 01Sale63.16996,25314,880Nov 05 07:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 31Option Exercise12.9910,000129,90055,740Nov 04 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 31Sale62.7210,000627,15545,740Nov 04 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 16Option Exercise12.992,00025,98047,740Oct 18 05:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 16Sale67.732,000135,45045,740Oct 18 05:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 10Sale66.763,000200,29145,740Oct 15 08:17 PM
FUCHS HENRY JEVP, Chief Medical OfficerSep 19Option Exercise11.0510,000110,50053,266Sep 23 04:37 PM
FUCHS HENRY JEVP, Chief Medical OfficerSep 19Sale80.1910,000801,90043,266Sep 23 04:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 16Option Exercise12.992,00025,98050,740Sep 18 02:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 16Sale73.082,000146,16348,740Sep 18 02:35 PM
BAFFI ROBERTEVP, Technical OperationsSep 09Option Exercise21.5120,000430,20082,262Sep 11 09:58 AM
BAFFI ROBERTEVP, Technical OperationsSep 09Sale73.0020,0001,460,00062,262Sep 11 09:58 AM
FUCHS HENRY JEVP, Chief Medical OfficerSep 05Option Exercise11.0510,000110,50053,266Sep 09 05:13 PM
FUCHS HENRY JEVP, Chief Medical OfficerSep 05Sale70.0010,000700,00043,266Sep 09 05:13 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 04Option Exercise39.069,000351,54046,950Sep 05 06:51 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 04Sale69.009,000621,00037,950Sep 05 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 15Option Exercise12.991,00012,99049,740Aug 19 05:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 15Sale64.361,00064,36448,740Aug 19 05:10 PM